Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1999;99:2791-2797

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kupferwasser, L. I.
Right arrow Articles by Bayer, A. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kupferwasser, L. I.
Right arrow Articles by Bayer, A. S.
Related Collections
Right arrow Infectious endocarditis
Right arrow Cardiovascular Pharmacology

(Circulation. 1999;99:2791-2797.)
© 1999 American Heart Association, Inc.


Basic Science Reports

Acetylsalicylic Acid Reduces Vegetation Bacterial Density, Hematogenous Bacterial Dissemination, and Frequency of Embolic Events in Experimental Staphylococcus aureus Endocarditis Through Antiplatelet and Antibacterial Effects

Presented in part at the 71st Scientific Sessions of the American Heart Association, Dallas, Tex, November 8–11, 1998, and published in abstract form (Circulation. 1998;98[suppl I]:I-700.)

Leon Iri Kupferwasser, MD; Michael R. Yeaman, PhD; Shelley M. Shapiro, MD, PhD; Cynthia C. Nast, MD; Paul M. Sullam, MD; Scott G. Filler, MD; Arnold S. Bayer, MD

From the Division of Adult Infectious Diseases (L.I.K., M.R.Y., S.G.F., A.S.B.) and Division of Cardiology (S.M.S.), St. John's Cardiovascular Research Center, Harbor–UCLA Medical Center, Torrance, Calif; UCLA School of Medicine (M.R.Y., S.M.S., S.G.F., A.S.B.), Los Angeles, Calif; Department of Pathology (C.C.N.), Cedars–Sinai Medical Center, Los Angeles, Calif; and Veterans Affairs Medical Center and University of California San Francisco (P.M.S.), San Francisco, Calif.

Correspondence to Leon Iri Kupferwasser, MD, Division of Infectious Diseases, LAC–Harbor UCLA Medical Center, 1000 W Carson St, Torrance, CA 90509 . E-mail kupferwasser{at}humc.edu

Background—Platelets are integral to cardiac vegetations that evolve in infectious endocarditis. It has been postulated that the antiplatelet aggregation effect of aspirin (ASA) might diminish vegetation evolution and embolic rates.

Methods and Results—Rabbits with Staphylococcus aureus endocarditis were given either no ASA (controls) or ASA at 4, 8, or 12 mg · kg-1 · d-1 IV for 3 days beginning 1 day after infection. Vegetation weights and serial echocardiographic vegetation size, vegetation and kidney bacterial densities, and extent of renal embolization were evaluated. In addition, the effect of ASA on early S aureus adherence to sterile vegetations was assessed. In vitro, bacterial adherence to platelets, fibrin matrices, or fibrin-platelet matrices was quantified with either platelets exposed to ASA or S aureus preexposed to salicylic acid (SAL). ASA at 8 mg · kg-1 · d-1 (but not at 4 or 12 mg · kg-1 · d-1) was associated with substantial decreases in vegetation weight (P<0.05), echocardiographic vegetation growth (P<0.001), vegetation (P<0.05) and renal bacterial densities and renal embolic lesions (P<0.05) versus controls. Diminished aggregation resulted when platelets were preexposed to ASA or when S aureus was preexposed to SAL (P<0.05). S aureus adherence to sterile vegetations (P<0.05) or to platelets in suspension (P<0.05), fibrin matrices (P<0.05), or fibrin-platelet matrices (P<0.05) was significantly reduced when bacteria were preexposed to SAL.

Conclusions—ASA reduces several principal indicators of severity and metastatic events in experimental S aureus endocarditis. These benefits involve ASA effects on both the platelet and the microbe.


Key Words: aspirin • embolism • endocarditis • platelets • fibrin




This article has been cited by other articles:


Home page
Eur Heart JHome page
Endorsed by the European Society of Clinical Micro, Authors/Task Force Members, G. Habib, B. Hoen, P. Tornos, F. Thuny, B. Prendergast, I. Vilacosta, P. Moreillon, M. de Jesus Antunes, et al.
Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): The Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC)
Eur. Heart J., October 1, 2009; 30(19): 2369 - 2413.
[Full Text] [PDF]


Home page
ESC Textbook of Cardiovascular MedicineHome page
W. G. Daniel and F. A. Flachskampf
CHAPTER 22 Infective Endocarditis
ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
M. B. K. Bandara, H. Zhu, P. R. Sankaridurg, and M. D. P. Willcox
Salicylic Acid Reduces the Production of Several Potential Virulence Factors of Pseudomonas aeruginosa Associated with Microbial Keratitis.
Invest. Ophthalmol. Vis. Sci., October 1, 2006; 47(10): 4453 - 4460.
[Abstract] [Full Text] [PDF]


Home page
J. Bacteriol.Home page
M. Palma, A. Bayer, L. I. Kupferwasser, T. Joska, M. R. Yeaman, and A. Cheung
Salicylic Acid Activates Sigma Factor B by rsbU-Dependent and -Independent Mechanisms.
J. Bacteriol., August 1, 2006; 188(16): 5896 - 5903.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
B. Prithiviraj, H. P. Bais, T. Weir, B. Suresh, E. H. Najarro, B. V. Dayakar, H. P. Schweizer, and J. M. Vivanco
Down Regulation of Virulence Factors of Pseudomonas aeruginosa by Salicylic Acid Attenuates Its Virulence on Arabidopsis thaliana and Caenorhabditis elegans
Infect. Immun., September 1, 2005; 73(9): 5319 - 5328.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
P. J. Domanski, P. R. Patel, A. S. Bayer, L. Zhang, A. E. Hall, P. J. Syribeys, E. L. Gorovits, D. Bryant, J. H. Vernachio, J. T. Hutchins, et al.
Characterization of a Humanized Monoclonal Antibody Recognizing Clumping Factor A Expressed by Staphylococcus aureus
Infect. Immun., August 1, 2005; 73(8): 5229 - 5232.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
L. M. Baddour, W. R. Wilson, A. S. Bayer, V. G. Fowler Jr, A. F. Bolger, M. E. Levison, P. Ferrieri, M. A. Gerber, L. Y. Tani, M. H. Gewitz, et al.
Infective Endocarditis: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: Endorsed by the Infectious Diseases Society of America
Circulation, June 14, 2005; 111(23): e394 - e434.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
D. R. Clifton, E. Rydkina, R. S. Freeman, and S. K. Sahni
NF-{kappa}B Activation during Rickettsia rickettsii Infection of Endothelial Cells Involves the Activation of Catalytic I{kappa}B Kinases IKK{alpha} and IKK{beta} and Phosphorylation-Proteolysis of the Inhibitor Protein I{kappa}B{alpha}
Infect. Immun., January 1, 2005; 73(1): 155 - 165.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. Niemann, N. Spehr, H. Van Aken, E. Morgenstern, G. Peters, M. Herrmann, and B. E. Kehrel
Soluble Fibrin Is the Main Mediator of Staphylococcus aureus Adhesion to Platelets
Circulation, July 13, 2004; 110(2): 193 - 200.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
Y.-Q. Xiong, A. S. Bayer, M. R. Yeaman, W. van Wamel, A. C. Manna, and A. L. Cheung
Impacts of sarA and agr in Staphylococcus aureus Strain Newman on Fibronectin-Binding Protein A Gene Expression and Fibronectin Adherence Capacity In Vitro and in Experimental Infective Endocarditis
Infect. Immun., March 1, 2004; 72(3): 1832 - 1836.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
Task Force Members, D. Horstkotte, F. Follath, E. Gutschik, M. Lengyel, A. Oto, A. Pavie, J. Soler-Soler, G. Thiene, A. von Graevenitz, et al.
Guidelines on Prevention, Diagnosis and Treatment of Infective Endocarditis Executive Summary: The Task Force on Infective Endocarditis of the European Society of Cardiology
Eur. Heart J., February 1, 2004; 25(3): 267 - 276.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
K.-L. Chan, J. G. Dumesnil, B. Cujec, A. J. Sanfilippo, J. Jue, M. A. Turek, T. I. Robinson, D. Moher, and Investigators of the Multicenter Aspirin Study in
A randomized trial of aspirin on the risk of embolic events in patients with infective endocarditis
J. Am. Coll. Cardiol., September 3, 2003; 42(5): 775 - 780.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. Homma and C. Grahame-Clarke
Toward reducing embolic complications from endocarditis
J. Am. Coll. Cardiol., September 3, 2003; 42(5): 781 - 783.
[Full Text] [PDF]


Home page
BloodHome page
U. Sjobring, U. Ringdahl, and Z. M. Ruggeri
Induction of platelet thrombi by bacteria and antibodies
Blood, December 15, 2002; 100(13): 4470 - 4477.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
L. I. Kupferwasser, M. R. Yeaman, S. M. Shapiro, C. C. Nast, and A. S. Bayer
In Vitro Susceptibility to Thrombin-Induced Platelet Microbicidal Protein Is Associated With Reduced Disease Progression and Complication Rates in Experimental Staphylococcus aureus Endocarditis: Microbiological, Histopathologic, and Echocardiographic Analyses
Circulation, February 12, 2002; 105(6): 746 - 752.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
E. Mylonakis and S. B. Calderwood
Infective Endocarditis in Adults
N. Engl. J. Med., November 1, 2001; 345(18): 1318 - 1330.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. Shapiro and L. I. Kupferwasser
Echocardiography predicts embolic events in infective endocarditis
J. Am. Coll. Cardiol., March 15, 2001; 37(4): 1077 - 1079.
[Full Text] [PDF]